8-K: Sarepta Therapeutics Q2 2026 Earnings: Revenue Dip, Profitability Holds

Sarepta Therapeutics reported Q2 2026 results with $328.7 million in net product revenue and achieved both GAAP and non-GAAP operating profitability, while narrowing full-year revenue guidance.

Summary

• Sarepta Therapeutics announced its second quarter 2026 financial results, reporting total net product revenues of $328.7 million, comprising $230.6 million from PMO therapies and $98.1 million from ELEVIDYS.
• The company achieved GAAP operating income of $13.3 million and non-GAAP operating income of $86.5 million for the quarter.
• Total revenues for Q2 2026 were $401.3 million, a decrease from $611.1 million in Q2 2025, primarily due to lower ELEVIDYS sales following an updated label and a decrease in collaboration revenue.
• Research and development expenses decreased significantly to $91.3 million in Q2 2026 from $204.4 million in Q2 2025, attributed to pipeline reprioritization and restructuring.
• Selling, general, and administrative expenses also decreased to $107.6 million from $137.9 million in the same period.
• A litigation contingency charge of $39.0 million was recorded in Q2 2026 related to potential patent litigation resolution.
• The company ended the quarter with approximately $945.0 million in cash, cash equivalents, restricted cash, and investments.
• Sarepta narrowed its full-year 2026 total net product revenue guidance to $1.2-$1.3 billion and its non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic report, with strong operational performance offset by a revenue decline and a significant litigation charge.

Positives

• Achieved GAAP operating income of $13.3 million and non-GAAP operating income of $86.5 million in Q2 2026, demonstrating profitability.
• Ended the quarter with a strong cash position of approximately $945.0 million, an increase of $197.0 million from the previous quarter.
• Successfully narrowed full-year 2026 guidance for both revenue and expenses, indicating better cost control and revenue visibility.
• Appointed Michael Severino, MD, as CEO, bringing extensive biopharma leadership experience.
• Key clinical milestones for DM1 and FSHD programs remain on track for the second half of 2026.
• FDA accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45 and VYONDYS 53, seeking conversion to traditional approval.

Negatives

• Total revenues decreased by 34% to $401.3 million in Q2 2026 compared to $611.1 million in Q2 2025.
• Net product revenues for Q2 2026 were $328.7 million, a decrease from the prior year period.
• GAAP net loss of $4.9 million in Q2 2026, compared to a net income of $196.9 million in Q2 2025.
• GAAP diluted earnings per share was $(0.05) in Q2 2026, down from $1.89 in Q2 2025.
• Recorded a $39.0 million litigation contingency charge.
• ELEVIDYS sales decreased due to an updated label restricting its use to ambulatory patients.

Risks

• Potential resolution of patent litigations, with a $39.0 million contingency charge already recorded.
• Continued reliance on regulatory approvals and potential for limitations on FDA's reliance on real-world evidence for traditional approval of casimersen and golodirsen.
• The updated ELEVIDYS label, limiting its use to ambulatory patients, may impact future sales.
• Potential for unforeseen adverse events or side effects from approved products or product candidates.
• Risks associated with clinical trial success, regulatory approval, and market adoption of pipeline candidates.
• Competition and market dynamics within the rare disease genetic medicine space.

Future Outlook

Sarepta has narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and its combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million. Key upcoming milestones include data readouts for DM1 and FSHD in the second half of 2026, full enrollment of ENDEAVOR Cohort 8 for ELEVIDYS by year-end 2026, and Q1 2027 for 12-week data from that cohort.

Management Comments

• "As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead," said Michael Severino, MD, chief executive officer, Sarepta Therapeutics.
• "Our second quarter results, including $328.7 million in total net product revenue and both GAAP and non-GAAP operating profitability, reflect the strength and resilience of our business."
• "With important data readouts expected in DM1 and FSHD, continued progress across our broader pipeline, and a talented team dedicated to transforming the lives of patients with rare diseases, we have significant opportunities ahead and remain committed to delivering sustainable long-term value."
• "Our priorities are clear: execute our commercial strategy, advance our promising siRNA pipeline, and continue allocating capital with discipline."
• "With a strong balance sheet, an innovative pipeline, and an experienced leadership team, I believe Sarepta is well positioned to deliver on its long-term potential."

Industry Context

StockSavvy.ai notes that Sarepta's results reflect the challenging market dynamics for gene and RNA therapies, particularly concerning label expansions and reimbursement. The revenue decline for ELEVIDYS due to its updated label highlights the sensitivity of these advanced therapies to regulatory and commercial positioning. The company's focus on pipeline advancement in DM1 and FSHD, alongside its established PMO therapies, aligns with industry trends of diversifying portfolios in rare genetic diseases.

Management Changes

Legal Proceedings

• A litigation contingency charge of $39.0 million was recorded related to the potential resolution of certain patent litigations, with definitive documentation still subject to negotiation.

Stakeholder Impact

• Shareholders: Revenue decline and a significant litigation charge may impact stock price, while profitability and a strong cash position offer some stability. Narrowed guidance provides more clarity.
• Patients: Continued focus on advancing therapies for rare diseases like DM1, FSHD, and DMD, with key clinical milestones expected.
• Employees: Restructuring efforts have led to reduced R&D and SG&A expenses, potentially impacting workforce size and focus.
• Partners (e.g., Roche): Contract manufacturing revenues increased due to higher ELEVIDYS supply to Roche, indicating ongoing collaboration.

Next Steps

• Continue execution of commercial strategy.
• Advance promising siRNA pipeline.
• Allocate capital with discipline.
• Achieve full enrollment of ENDEAVOR Cohort 8 for ELEVIDYS by year-end 2026.
• Report 12-week data from ENDEAVOR Cohort 8 in Q1 2027.
• Report data readouts from DM1 and FSHD programs in 2H 2026.

Key Dates

Recommendation

The company demonstrates operational resilience with profitability and a strong cash position despite a revenue decline and a significant litigation charge. The narrowed guidance and upcoming clinical milestones offer some positive outlook, but the revenue decrease and the uncertainty surrounding the litigation warrant a cautious 'hold' stance until further clarity emerges.

Keywords

Duchenne Muscular Dystrophy, Genetic Medicine, Rare Diseases, DMD, Micro-dystrophin, Gene Therapy, RNA Therapy, Clinical Trials